20
total announcements
WANBURY.NS · 15 min delayed
Wanbury Limited
Wanbury Limited has informed the Exchange about Copy of Newspaper Publication regarding 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11:30 a.m. through Video Conferencing (VC)/Other Audio Visual Means (OAVM).
Wanbury Limited
Wanbury Limited has received approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new product Rivaroxaban API, and also received DMF clearance for Paraxetine HCI and Metformin HCI from the USFDA.
Wanbury Limited
Wanbury Limited has announced its un-audited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 165.6 crore, a growth of 1.5% YoY. Gross profit stood at Rs. 86.9 crore, with a gross margin contraction to 52.5% due to an unprecedented sudden increase in input costs. EBITDA stood at Rs. 16.6 crore, with an EBITDA margin at 10.0%. PAT stood at Rs. 3.2 crore, with EPS of Rs. 0.93.
Wanbury Limited
Wanbury Limited has informed the Exchange regarding allotment of 27,530 securities pursuant to ESOP/ESPS at its meeting held on August 11, 2026, and also announced its un-audited financial results for the first quarter and three months ended June 30, 2026, along with the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director.
Wanbury Limited
Wanbury Limited has informed the Exchange about change in Management, with the Board of Directors approving the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a term of five years, and the allotment of 27,530 Equity Shares to eligible employees upon exercise of vested options.
Wanbury Limited
Wanbury Limited has submitted its financial results for the period ended June 30, 2026, and approved the allotment of 27,530 equity shares to eligible employees under the Employee Stock Option Plan 2016. The company also re-appointed Mr. Mohan Kumar Rayana as a Whole-time Director for a term of five years.
Wanbury Limited
Wanbury Limited has informed the Exchange that it has received a 'No DMF deficiency letter' from the USFDA for multiple ANDAs, indicating full compliance with regulatory requirements.
Wanbury Limited
Wanbury Limited has informed the Exchange about General Updates, specifically the completion of a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA) at the Company's facility at Tanuku, West Godavari District, Andhra Pradesh. The inspection resulted in six observations, and the Company will respond to these observations within the stipulated time.
Wanbury Limited
Wanbury Limited has informed the Exchange about the completion of a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA) at its facility in Tanuku, West Godavari District, Andhra Pradesh. The inspection was conducted from July 13, 2026 to July 17, 2026, and the USFDA issued a Form 483 with six observations. The company will respond to these observations within the stipulated time.
Wanbury Limited
Wanbury Limited's price movement has been observed, prompting the exchange to request clarification. The company has responded, stating that the information required to be disclosed has already been provided under Regulation 30 of the SEBI (LODR) Regulations, 2015, and there are no other material events or information that need to be informed at this time.
Wanbury Limited
Wanbury Limited's stock price has shown significant movement, prompting the exchange to reach out to the company for clarification, awaiting the company's response.
Wanbury Limited
Wanbury Limited has informed the Exchange about the early redemption of 12.5% secured, guaranteed, senior, taxable, non-cumulative, unrated, redeemable, principal protected non-convertible debentures.
Wanbury Limited
Wanbury Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of securities during the quarter ended June, 2026.
Wanbury Limited
Wanbury Limited has informed the Exchange about Investor Presentation, which includes audited financial results for the quarter and year ended 31st March, 2026, and is available on the company's website.
Wanbury Limited
Wanbury Limited has informed the Exchange regarding Change in Auditors of the company. The Board of Directors has approved the appointment of Internal Auditor and Cost Auditor for the Financial Year 2026-2027.
Wanbury Limited
Wanbury Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2026, where the Board of Directors approved the incorporation of a subsidiary company in India with an estimate aggregate capital outlay of ~ 4,10,000/- (Rupees Four Lakh and Ten Thousand only) and appointed Internal Auditor and Cost Auditor.
Wanbury Limited
Wanbury Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2026, where the Board of Directors approved the incorporation of a subsidiary company in India with an estimate aggregate capital outlay of ~ 4,10,000/- (Rupees Four Lakh and Ten Thousand only) and appointed Internal Auditor and Cost Auditor.
Wanbury Limited
Wanbury Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities of the Company shall continue to remain close for the Designated Persons till 48 hours after the declaration of Unaudited Financial Results (UFR) of the Company for the quarter ended 30th June, 2026.
Wanbury Limited
Wanbury Limited has informed the Exchange regarding a press release dated Jun 25, 2026, titled "Intimation of pledge being released on equity shares held by the Promoter Group and reduction in rate of Interest from 12.5% per annum to Sub 10% per annum." The existing debt facilities of the Company have been taken over by Axis Finance Limited & Poonawala Fincorp, and the pledge created on the equity shares of the Company held by members of the Promoter Group is being released to the full extent earlier held by Investec AIF & Tata Capital Limited.
Wanbury Limited
Wanbury Limited has submitted a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This declaration was provided by Expert Chemicals (India) Private Limited, addressing the stock exchanges and Wanbury's Audit Committee. Regulation 31(4) typically involves an acquirer reaffirming their compliance with specific conditions that grant them an exemption from making an open offer, despite holding or increasing a significant stake. For investors, this indicates that Expert Chemicals is continuing to operate within the existing regulatory framework regarding its shareholding in Wanbury, without triggering new open offer requirements.